Webcast is Live at 7:30 a.m. (CT)
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in
vitro diagnostic technologies to the healthcare industry, today
announced that it will host a live webcast of its fourth quarter and
fiscal year 2016 conference call on Wednesday, November 16, at 7:30 a.m.
CT (8:30 a.m. ET). The Company will issue an earnings news release
earlier that morning.
Gary Maharaj, president and chief executive officer, and Andy LaFrence,
vice president of finance and information systems and chief financial
officer, will recap the fourth quarter and fiscal year 2016 financial
results and accomplishments as well as provide 2017 guidance. To access
the webcast, go to the investor relations portion of the Company’s
website at www.surmodics.com
the day of the conference call and click on the webcast icon.
An audio replay will be available beginning at 10:30 a.m. CT on
Wednesday, November 16, until 10:30 a.m. CT on Wednesday, November 23,
and can be accessed by dialing 888-203-1112 and entering conference call
ID passcode 8067923. In addition, the conference call audio and
transcript will be archived on the Company’s website following the call.
About Surmodics, Inc.
Surmodics is the global leader in surface modification technologies for
intravascular medical devices and a leading provider of chemical
components for in vitro diagnostic (IVD) tests and microarrays.
Following two recent acquisitions of Creagh Medical and NorMedix, the
Company is executing a key growth strategy for its medical device
business by expanding to offer total intravascular product solutions to
its medical device customers. The combination of proprietary surface
technologies, along with enhanced device design, development and
manufacturing capabilities, enables Surmodics to significantly increase
the value it offers with highly differentiated intravascular solutions
designed and engineered to meet the most demanding requirements. With
this focus on offering total product solutions, Surmodics’ mission
remains to improve the detection and treatment of disease by using its
technology to provide solutions to difficult medical device and
diagnostic challenges. Surmodics is headquartered in Eden Prairie,
Minnesota. For more information about the company, visit www.surmodics.com.
The content of Surmodics’ website is not part of this press release or
part of any filings that the company makes with the SEC.